Completed NA INTERVENTIONAL 1-arm NCT01238393

Treatment of Epiretinal Membranes With Ranibizumab (LERM)

A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study

Sponsor: Queen's University

Updated 8 times since 2017 Last updated: Jan 12, 2016 Started: Nov 30, 2010 Primary completion: Nov 30, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01238393, this NA trial focuses on Epiretinal Membrane and remains completed. Sponsored by Queen's University, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Jun 2025 — Present [monthly]

Completed NA
Apr 2025 — Jun 2025 [monthly]

Completed NA
Sep 2024 — Apr 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Queen's University

Data source: Queen's University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kingston, Canada